+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Drugs Market - Global Forecast 2026-2032- Product Image
Type 2 Diabetes Drugs Market - Global Forecast 2026-2032- Product Image
New

Type 2 Diabetes Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666390
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Type 2 diabetes drugs market is experiencing rapid evolution as clinical, regulatory, and commercial imperatives converge to reshape patient care pathways, innovation priorities, and supplier strategies. Senior leaders face a landscape defined by advanced therapeutics, shifting patient expectations, and new operational challenges.

Market Snapshot: Type 2 Diabetes Drugs Market

The Type 2 diabetes drugs market grew from USD 1.76 billion in 2025 to USD 1.89 billion in 2026. It is projected to expand at a CAGR of 7.41%, reaching USD 2.91 billion by 2032.

Scope & Segmentation

This report provides a comprehensive lens on the changing Type 2 diabetes therapeutic ecosystem, offering insight into evolving treatment standards, drug innovation, and strategic market access:

  • Drug Classes: Biguanides, DPP-4 inhibitors, GLP-1 receptor agonists, insulin variants, SGLT2 inhibitors, sulfonylureas, thiazolidinediones.
  • Formulation Differentiation: Combination formulations, extended and immediate release (within Biguanides); assessment of specific agents within each class considering clinical benefits, tolerability, and renal profile.
  • Administration Formats: Injectables (pen devices, prefilled syringes), oral therapies (capsules, tablets).
  • Treatment Lines: Monotherapy, dual and triple therapy combinations; primary, secondary, and tertiary lines of treatment.
  • Distribution Channels: Hospital, retail pharmacy, and online pharmacy channels impacting patient access and launch strategy.
  • Brand Types: Branded versus generic products influencing pricing, lifecycle management, and payer alignment.
  • Patient Demographics: Segmentation by age and gender, linked to adherence interventions and real-world outcome generation.
  • Geographic Coverage: Americas; Europe, Middle East & Africa; Asia-Pacific, each with unique regulatory, access, and market entry requirements.

Key Takeaways: Strategic Insights

  • Recent therapeutic advances have broadened treatment goals, with innovations now addressing not only glucose management but also cardiovascular, renal, and weight-related outcomes.
  • Patient expectations and real-world use trends require commercial strategies that prioritize safety, adherence, and proven outcome benefits.
  • Digital adherence solutions and new administration formats are reshaping prescribing patterns and enhancing chronic disease management outside traditional settings.
  • Clinical differentiation alone is no longer sufficient; manufacturers must integrate outcome data, regulatory intelligence, and market access strategies to maintain competitive relevance.
  • Distribution and product positioning hinge on evidence tailored to diverse regional payer and regulatory environments, demanding nuanced access playbooks for each market.

Tariff Impact on Supply Chains and Manufacturing

Tariff policy changes are driving increased operational complexity for Type 2 diabetes drug manufacturers. Higher costs on active ingredients, packaging, and finished products have prompted firms to reassess supplier diversification, pursue nearshoring, and recalibrate logistics to reduce exposure. These shifts necessitate fresh capital investment and can complicate regulatory compliance, as changing manufacturing locations or packaging often requires resubmission to authorities and additional audits. Integrating tariff-driven insight into supply contracts, inventory management, and clinical trial planning is essential for safeguarding both continuity of supply and cost structures.

Methodology & Data Sources

The research utilizes a mixed-methods approach. Primary insights stem from targeted interviews with clinicians, payers, distribution experts, and industry leaders. Secondary validation comes from peer-reviewed clinical studies, regulatory documents, and published policy analyses. Analytical frameworks segment the market by drug class, route, treatment lines, and distribution to ensure robust, actionable findings.

Why This Report Matters

  • Provides actionable intelligence that supports resilient commercial, clinical, and supply chain strategies amid ongoing disruption.
  • Equips decision-makers with precise, segmentation-driven insights for tailoring product strategy and access initiatives in diverse regional contexts.
  • Enables the alignment of R&D, operational, and go-to-market planning with measurable patient and system-level benefits.

Conclusion

Senior stakeholders can leverage this report to align clinical, operational, and market-facing strategies for long-term sustainability in the evolving Type 2 diabetes therapeutic sector. Integrated, evidence-driven approaches will be vital for maintaining relevance and delivering value to both patients and healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Type 2 Diabetes Drugs Market, by Drug Class
8.1. Biguanides
8.1.1. Combination Formulations
8.1.2. Extended Release
8.1.3. Immediate Release
8.2. DPP-4 Inhibitors
8.2.1. Alogliptin
8.2.2. Linagliptin
8.2.3. Saxagliptin
8.2.4. Sitagliptin
8.3. GLP-1 Receptor Agonists
8.3.1. Dulaglutide
8.3.2. Exenatide
8.3.3. Liraglutide
8.3.4. Semaglutide
8.4. Insulin
8.4.1. Basal
8.4.1.1. Degludec
8.4.1.2. Detemir
8.4.1.3. Glargine
8.4.2. Prandial
8.4.2.1. Aspart
8.4.2.2. Glulisine
8.4.2.3. Lispro
8.4.3. Premixed
8.4.3.1. 50/50 Mix
8.4.3.2. 70/30 Mix
8.4.3.3. 75/25 Mix
8.5. SGLT2 Inhibitors
8.5.1. Canagliflozin
8.5.2. Dapagliflozin
8.5.3. Empagliflozin
8.5.4. Ertugliflozin
8.6. Sulfonylureas
8.6.1. Chlorpropamide
8.6.2. Glimepiride
8.6.3. Glipizide
8.6.4. Glyburide
8.7. Thiazolidinediones
8.7.1. Pioglitazone
8.7.2. Rosiglitazone
9. Type 2 Diabetes Drugs Market, by Route Of Administration
9.1. Injectable
9.1.1. Pen
9.1.2. PreFilled Syringe
9.2. Oral
9.2.1. Capsule
9.2.2. Tablet
10. Type 2 Diabetes Drugs Market, by Treatment Line
10.1. First Line
10.1.1. Combination
10.1.1.1. Dual Therapy
10.1.1.2. Triple Therapy
10.1.2. Monotherapy
10.2. Second Line
10.3. Third Line
11. Type 2 Diabetes Drugs Market, by Brand Type
11.1. Branded
11.2. Generic
12. Type 2 Diabetes Drugs Market, by Patient Age Group
12.1. 18 To 65
12.2. Above 65
13. Type 2 Diabetes Drugs Market, by Patient Gender
13.1. Female
13.2. Male
14. Type 2 Diabetes Drugs Market, by Distribution Channel
14.1. Hospital Pharmacy
14.2. Online Pharmacy
14.3. Retail Pharmacy
15. Type 2 Diabetes Drugs Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Type 2 Diabetes Drugs Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Type 2 Diabetes Drugs Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Type 2 Diabetes Drugs Market
19. China Type 2 Diabetes Drugs Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Astellas Pharma Inc.
20.6. AstraZeneca PLC
20.7. Bayer AG
20.8. Biocon Limited
20.9. Boehringer Ingelheim International GmbH
20.10. Bristol-Myers Squibb Company
20.11. Chong Kun Dang Pharmaceutical Corp.
20.12. Eli Lilly and Company
20.13. Gilead Sciences, Inc.
20.14. Hanmi Pharmaceutical Co., Ltd.
20.15. Innovent Biologics Co., Ltd.
20.16. Johnson & Johnson Services, Inc.
20.17. Merck & Co., Inc.
20.18. Novartis AG
20.19. Novo Nordisk A/S
20.20. Oramed Pharmaceuticals, Inc.
20.21. Pfizer Inc.
20.22. Sanofi S.A.
20.23. Takeda Pharmaceutical Company Limited
20.24. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY REGION, 2018-2032 (USD MILLION)
TABLE 190. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY GROUP, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 193. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 197. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 202. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 208. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 210. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 211. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 213. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 215. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 216. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 217. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 218. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 219. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 220. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 221. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 222. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 224. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 225. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 226. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 227. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 228. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 229. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 230. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 231. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 234. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 235. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 237. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 238. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 239. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 240. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 241. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 243. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 244. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 245. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 246. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 247. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 248. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 249. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 250. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 251. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 252. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 253. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 255. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 256. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 257. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 259. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 260. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 261. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 262. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 263. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 264. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 265. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 266. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 267. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 268. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 269. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 270. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 271. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 272. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 273. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 274. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 275. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 298. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 299. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 300. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
TABLE 301. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 302. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 303. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 304. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
TABLE 305. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
TABLE 306. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
TABLE 307. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 308. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
TABLE 309. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
TABLE 310. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 311. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 312. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 313. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 314. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 315. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
TABLE 316. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
TABLE 317. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 318. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
TABLE 319. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 320. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 321. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD

Companies Mentioned

The key companies profiled in this Type 2 Diabetes Drugs market report include:
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.89 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.91 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Type 2 Diabete Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Type 2 Diabete Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 142 Pages
  • Global
From
Type 2 Diabetes Drug Pipeline Analysis Report 2025 - Product Image

Type 2 Diabetes Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Type 2 Diabetes Mellitus Treatment Market - Global Forecast 2025-2030 - Product Image

Type 2 Diabetes Mellitus Treatment Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Antidiabetic Drugs Market - Global Forecast 2026-2032 - Product Image

Antidiabetic Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Type 2 Diabetes Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Type 2 Diabetes Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From

About the Type 2 Diabetes Drug Market

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.